Skip to main content
SpringerLink
Log in

Efficacy of sotalol in controlling reentrant supraventricular tachycardias

  • Class III Activity: The Utility of Sotalol
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Sotalol is unique among beta-blocking agents having significant Class III antiarrhythmic action. In a series of 22 patients with Wolff-Parkinson-White (WPW) syndrome and seven patients with artrioventricular nodal reentry tachycardia (AVNRT) resistant to multiple drugs, sotalol was studied by acute electrophysiologic means, as well as by long-term clinical follow-up ranging from 1 to 47 months. Sustained reciprocating tachycardia was rendered noninducible in 13 of 18 patients with WPW and in 5 of 6 with AVNRT. Long-term control of symptomatic tachycardia was achieved in 77% of patients with WPW and in 57% of patients with resistant AVNRT. Side effects were those associated with beta blockade. Two patients developed ventricular irritability associated with excessive QT prolongation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaumann AJ, Olson CB. Temporal relation between long-lasting aftercontractions and action potentials in cat papillary muscles. Science 1968;161:293–295.

    Google Scholar 

  2. Singh BN, Vaughan Williams EM. A third class of antiarrythmic action, effects on atrial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle of MJ1999 and AM3474. Br J Pharmacol 1970; 39:675–687.

    Google Scholar 

  3. Prakash R, Parmley WW, Allen HN, Matloff JM. Effect of sotalol in clinical arrhythmias. Am J Cardiol 1972;29:397–400.

    Google Scholar 

  4. Rizos I, Senges J, Jauernig R, et al. Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia. Am J Cardiol 1984;53:1022–1027.

    Google Scholar 

  5. Schofield PM, Reid F, Bennett DH. A comparison of atenalol and sotalol in the treatment of patients with paroxysmal supraventricular tachycardia (abstract). Pace 1987; 10:740.

    Google Scholar 

  6. Echt DS, Berte LE, Clusin WT, et al. Prolongation of human cardiac monophasic action potential by sotalol. Am J Cardiol 1982;50:1082–1086.

    Google Scholar 

  7. Creamer JE, Nathan AW, Shennon A, Camm AJ. Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing. Am J Cardiol 1986;57:1092–1096.

    Google Scholar 

  8. Nathan AW, Hellestrand KJ, Bexton RS, et al. Electrophysiological effects of sotalol—just another beta-blocker? Br Heart J 1982;47:515–520.

    Google Scholar 

  9. Bennett DH. Acute prolongation of myocardial refractoriness by sotalol. Br Heart J 1982;47:521–526.

    Google Scholar 

  10. Scott Millar RN. Clinical and electrophysiological effects of sotalol in Wolff-Parkinson-White syndrome. In: Belhassen B, Feldman S, Copperman Y, eds. Cardiac pacing and electrophysiology. Tel Aviv, Israel: R & L Creative Communications, 1987:373–379.

    Google Scholar 

  11. Mitchell LB, Wyse DG, Duff HJ. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987;76:810–818.

    Google Scholar 

  12. Wellens HJJ, Lie KL, Bar FW, et al. Effect of amiodarone in the Wolff-Parkinson-White syndrome. Am J Cardiol 1976;38:189–194.

    Google Scholar 

  13. Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920;7:353–370.

    Google Scholar 

  14. McKibben JK, Pocock WA, Barlow JB et al. Sotalol hypokalemia, syncope, and torsade de pointes. Br Heart J 1984;51:157–162.

    Google Scholar 

  15. Gallagher JJ, Pritchett ELC, Sealy WC, et al. The preexcitation syndromes. Progr Cardiovasc Dis 1978;20:285–327.

    Google Scholar 

  16. Galumhusein S, Ko P, Carruthers G, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982;65:348–354.

    Google Scholar 

  17. Morady F, Dicarlo LA, Baerman JM, DeBuitleir M. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. Pace 1987;10:492–496.

    Google Scholar 

  18. Wellens HJJ, Bar FW, Dassen WRM, et al. Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of the effective refractory period of the accessory pathway. Am J Cardiol 1980;46:665–669.

    Google Scholar 

  19. Laakso M, Pentikainen PJ, Lampainen E. Sotalol, prolonged QT interval and ventricular tachyarrhythmias. Ann Clin Res 1981;13:439–440.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiac Clinic, Department of Medicine, Groote Schuur Hospital, South Africa

    R. N. Scott Millar

  2. University of Cape Town, Cape Town, South Africa

    R. N. Scott Millar

Authors
  1. R. N. Scott Millar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott Millar, R.N. Efficacy of sotalol in controlling reentrant supraventricular tachycardias. Cardiovascular Drugs and Therapy 4 (Suppl 3), 625–629 (1990). https://doi.org/10.1007/BF00357041

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00357041

Key Words

Search

Navigation